$BCLI
BRAINSTORM CELL THERAPEUTICS INC.

2023 Q4 Form 10-Q Financial Statement

#000141057823002443 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.106M $2.710M
YoY Change 26.06% -11.58%
% of Gross Profit
Research & Development $1.698M $3.330M
YoY Change -30.72% -11.81%
% of Gross Profit
Depreciation & Amortization $65.00K $65.00K
YoY Change -7.14% -7.14%
% of Gross Profit
Operating Expenses $4.804M $3.330M
YoY Change -2.26% -11.81%
Operating Profit -$6.035M
YoY Change -11.78%
Interest Expense -$236.0K $4.930M
YoY Change
% of Operating Profit
Other Income/Expense, Net -$538.0K -$120.0K
YoY Change 422.33% 605.88%
Pretax Income -$5.578M -$1.230M
YoY Change 11.16% -82.06%
Income Tax
% Of Pretax Income
Net Earnings -$5.578M -$1.226M
YoY Change 11.16% -82.12%
Net Earnings / Revenue
Basic Earnings Per Share -$0.03
Diluted Earnings Per Share -$0.11 -$0.03
COMMON SHARES
Basic Shares Outstanding 48.98M 45.02M
Diluted Shares Outstanding 44.25M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.300M $1.420M
YoY Change -56.42% -80.79%
Cash & Equivalents $1.300M $1.222M
Short-Term Investments $0.00 $200.0K
Other Short-Term Assets $548.0K $60.00K
YoY Change 1612.5% 17.65%
Inventory
Prepaid Expenses
Receivables $51.00K $70.00K
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.899M $1.539M
YoY Change -38.86% -79.49%
LONG-TERM ASSETS
Property, Plant & Equipment $686.0K $752.0K
YoY Change -26.47% -25.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.309M $4.143M
YoY Change -56.8% -27.97%
Total Long-Term Assets $2.309M $4.143M
YoY Change -56.8% -27.97%
TOTAL ASSETS
Total Short-Term Assets $1.899M $1.539M
Total Long-Term Assets $2.309M $4.143M
Total Assets $4.208M $5.682M
YoY Change -50.21% -57.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.954M $3.926M
YoY Change -20.4% -38.61%
Accrued Expenses $1.240M $63.00K
YoY Change 1376.19% 8.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.800M $6.321M
YoY Change -11.36% -29.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.266M $1.940M
YoY Change -52.51% -33.52%
Total Long-Term Liabilities $1.266M $1.943M
YoY Change -52.51% -33.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.800M $6.321M
Total Long-Term Liabilities $1.266M $1.943M
Total Liabilities $9.066M $8.264M
YoY Change -20.93% -30.36%
SHAREHOLDERS EQUITY
Retained Earnings -$215.0M -$209.0M
YoY Change 8.59% 8.29%
Common Stock $210.3M $207.0M
YoY Change 7.87% 6.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.858M -$2.582M
YoY Change
Total Liabilities & Shareholders Equity $4.208M $5.682M
YoY Change -50.21% -57.13%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$5.578M -$1.226M
YoY Change 11.16% -82.12%
Depreciation, Depletion And Amortization $65.00K $65.00K
YoY Change -7.14% -7.14%
Cash From Operating Activities -$3.288M -$6.409M
YoY Change -29.26% 32.14%
INVESTING ACTIVITIES
Capital Expenditures -$2.000K $18.00K
YoY Change 1700.0%
Acquisitions
YoY Change
Other Investing Activities $191.0K $10.00K
YoY Change -81.6% -200.0%
Cash From Investing Activities $193.0K -$12.00K
YoY Change -81.41% 9.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.348M 7.097M
YoY Change 1306.72%
NET CHANGE
Cash From Operating Activities -3.288M -6.409M
Cash From Investing Activities 193.0K -12.00K
Cash From Financing Activities 3.348M 7.097M
Net Change In Cash 253.0K 676.0K
YoY Change -107.5% -113.91%
FREE CASH FLOW
Cash From Operating Activities -$3.288M -$6.409M
Capital Expenditures -$2.000K $18.00K
Free Cash Flow -$3.286M -$6.427M
YoY Change -29.3% 32.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001137883
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45314961
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36694078
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36641
dei Entity Registrant Name
EntityRegistrantName
BRAINSTORM CELL THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-7273918
dei Entity Address Address Line1
EntityAddressAddressLine1
1325 Avenue of Americas, 28th Floor
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address City Or Town
EntityAddressCityOrTown
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
dei City Area Code
CityAreaCode
201
dei Local Phone Number
LocalPhoneNumber
488-0460
dei Security12b Title
Security12bTitle
Common Stock, $0.00005 par value
dei Trading Symbol
TradingSymbol
BCLI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48981588
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1222000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
772000
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
196000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
2211000
CY2023Q3 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
66000
CY2022Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
91000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
55000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
32000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
1539000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
3106000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
21000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
23000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3370000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4389000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
752000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
933000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4143000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5345000
CY2023Q3 us-gaap Assets
Assets
5682000
CY2022Q4 us-gaap Assets
Assets
8451000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3926000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6224000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
63000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
84000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1306000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1427000
CY2023Q3 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
1026000
CY2022Q4 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
1065000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6321000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8800000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1585000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2666000
CY2023Q3 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
358000
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1943000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2666000
CY2023Q3 us-gaap Liabilities
Liabilities
8264000
CY2022Q4 us-gaap Liabilities
Liabilities
11466000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
12000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45314961
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36694078
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
206957000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
194910000
CY2023Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-209435000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197821000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2582000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3015000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5682000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8451000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9048000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11505000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3330000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3776000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7587000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8402000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2705000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3065000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16635000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19907000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6035000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6841000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-91000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-648000
CY2023Q3 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
121000
CY2022Q3 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
17000
bcli Fair Value Adjustments Of Warrants And Stock Issuance Costs
FairValueAdjustmentsOfWarrantsAndStockIssuanceCosts
-4930000
CY2023Q3 bcli Fair Value Adjustments Of Warrants And Stock Issuance Costs
FairValueAdjustmentsOfWarrantsAndStockIssuanceCosts
-4930000
us-gaap Net Income Loss
NetIncomeLoss
-11614000
us-gaap Net Income Loss
NetIncomeLoss
-19259000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1226000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6858000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40255502
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40255502
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36472372
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36472372
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44251809
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44251809
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36493432
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36493432
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
19342000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
505000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5360000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
14487000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
405000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7041000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
7851000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
395000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6858000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1388000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3015000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4000
CY2023Q1 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
3230000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5059000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4840000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
988000
CY2023Q2 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
5299000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5329000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3882000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
548000
CY2023Q3 bcli Issuance Of Shares For Private Placement Value
IssuanceOfSharesForPrivatePlacementValue
1978000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1226000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2582000
us-gaap Profit Loss
ProfitLoss
-11614000
us-gaap Profit Loss
ProfitLoss
-19259000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-1226000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-6858000
us-gaap Depreciation
Depreciation
199000
us-gaap Depreciation
Depreciation
215000
CY2023Q3 us-gaap Depreciation
Depreciation
65000
CY2022Q3 us-gaap Depreciation
Depreciation
70000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1540000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1305000
CY2023Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
548000
CY2022Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
395000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-183000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-646000
CY2023Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-58000
CY2022Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-34000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-4000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-1081000
CY2023Q3 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-345000
CY2022Q3 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-457000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-298000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2695000
CY2023Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1264000
CY2022Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1103000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4761000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4761000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-60000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-63000
CY2023Q3 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-58000
CY2022Q3 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
17000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17173000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14672000
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6409000
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4850000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29000
CY2023Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18000
CY2022Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-2015000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
11000
CY2023Q3 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-6000
CY2022Q3 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
10000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1997000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-40000
CY2023Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12000
CY2022Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11000
bcli Proceeds From At Market
ProceedsFromAtMarket
8529000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7097000
CY2023Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7097000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15626000
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7097000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
450000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14712000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
676000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4861000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
772000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18856000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
546000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9005000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1222000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4144000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1222000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4144000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-209000000
us-gaap Use Of Estimates
UseOfEstimates
<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">D.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Use of estimates</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 82.8pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">​</span></p>
bcli Percentage Of Royalty Payment If Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05
bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3370000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2891000
us-gaap Operating Lease Payments
OperatingLeasePayments
1908000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M13D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0675
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
335000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1340000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1243000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
179000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3097000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
206000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2891000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161000000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0340
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0449
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.91
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.18
us-gaap Share Based Compensation
ShareBasedCompensation
1540000
us-gaap Share Based Compensation
ShareBasedCompensation
1305000

Files In Submission

Name View Source Status
bcli-20230930_lab.xml Edgar Link unprocessable
0001410578-23-002443-index-headers.html Edgar Link pending
0001410578-23-002443-index.html Edgar Link pending
0001410578-23-002443.txt Edgar Link pending
0001410578-23-002443-xbrl.zip Edgar Link pending
bcli-20230930.xsd Edgar Link pending
bcli-20230930x10q.htm Edgar Link pending
bcli-20230930xex31d1.htm Edgar Link pending
bcli-20230930xex31d2.htm Edgar Link pending
bcli-20230930xex31d3.htm Edgar Link pending
bcli-20230930xex32d1.htm Edgar Link pending
bcli-20230930xex32d2.htm Edgar Link pending
bcli-20230930xex32d3.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
bcli-20230930_cal.xml Edgar Link unprocessable
bcli-20230930_def.xml Edgar Link unprocessable
bcli-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bcli-20230930x10q_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending